Overview of 99mTc-anti-TNF-α scintigraphy: Diagnostic applications


Creative Commons License

Elboga U., Kalender E., Yalcin H.

Reports in Medical Imaging, cilt.7, sa.1, ss.1-3, 2014 (Scopus) identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 7 Sayı: 1
  • Basım Tarihi: 2014
  • Doi Numarası: 10.2147/rmi.s39098
  • Dergi Adı: Reports in Medical Imaging
  • Derginin Tarandığı İndeksler: Scopus
  • Sayfa Sayıları: ss.1-3
  • Anahtar Kelimeler: 99mTc tumor necrosis factor-α imaging, mAb, Monoclonal antibodies, Nuclear medicine
  • Hatay Mustafa Kemal Üniversitesi Adresli: Evet

Özet

Tumor necrosis factor alpha (TNF-α) has a role in the pathogenesis of several inflammatory diseases such as rheumatoid arthritis, Crohn's disease, and ulcerative colitis. As TNF-α plays a role in the pathogenesis of different inflammatory diseases, anti-TNF-α agents (monoclonal antibodies [mAbs]) such as infliximab, adalimumab, and certolizumab have been developed and investigated for the treatment of these conditions. In recent years, these mAbs also have been used for diagnosis, monitoring, follow-up of disease activity, and therapy decision-making for inflammatory diseases, especially rheumatoid arthritis, after labeling with 99mTc. However, 99mTc-anti-TNF-α imaging might have severe adverse effects and is expensive. In contrast, scintigraphic imaging before therapy with radiolabeled mAbs may be a cost-effective solution for therapy decisions. © 2014 Elboga et al.